CDMOs offering Sterile Fill-Finish & Aseptic Manufacturing with Gene Therapy

Matching companies

• AGC Biologics

  Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.

• Aldevron

  Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.

• Argonaut Manufacturing Services

  Argonaut is a sterile fill-finish CDMO specializing in isolator-based aseptic manufacturing for biologics, peptides, nucleic acids, lipid nanoparticles, gene therapies, and vaccines from preclinical through commercial scale, with FDA and Annex 1 compliance.

• Ascend

  Ascend is a gene-to-GMP development partner specializing in advanced biologics and vaccines with 60+ years of custom biologics expertise and 20+ years of AAV development capability. The company offers onsite fill-finish capabilities across multiple US locations and combines next-generation technologies with deep regulatory acumen.

• Ascendia Pharmaceutical Solutions

  Ascendia is a specialty CDMO providing formulation development, analytical services, and GMP manufacturing for small molecules and biologics from pre-formulation through commercialization, with proprietary nanotechnologies including LipidSol, EmulSol, AmorSol, and NanoSol.

• Biomay AG

  GMP CDMO specializing in plasmid DNA, mRNA, and recombinant protein manufacturing from gene construction to market supply, with in-house mRNA lipid-nanoparticle formulation and aseptic fill-finish capabilities.

• Catalent

  Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.

• Charles River Laboratories

  Charles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.

• FUJIFILM Biotechnologies

  CDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.

• Forge Biologics

  Dedicated AAV gene therapy CDMO with a 200,000+ sq. ft. cGMP facility featuring 20 suites and bioreactors up to 5,000L, supporting 60+ clients across 35+ indications with high-yield manufacturing and seamless regulatory compliance.

• National Resilience

  End-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.

• Oxford Biomedica

  Global viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.

• Patheon (Thermo Fisher Pharma Services)

  Patheon is a trusted global contract development and manufacturing organization (CDMO) partner owned by Thermo Fisher Scientific, offering 360° integrated solutions from early-stage R&D through clinical supply and commercial manufacturing.

• Pharmaron

  Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.

• Porton Advanced

  End-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.

• Siegfried Holding

  Global CDMO with 16 production sites across four continents, offering integrated development and manufacturing from early-phase to commercial scale for drug substance and drug product.

• Syngene International

  Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.

• Yapan Bio

  Yapan Bio provides integrated process development, characterization, and GMP manufacturing for vaccines, monoclonal antibodies, gene therapy, and viral vector-based biologics, with capabilities up to 1000L bioreactor scale and BSL-2+ containment.

• eXmoor Pharma

  Integrated cell and gene therapy CDMO with 20+ years of consultancy expertise, offering end-to-end CMC support from early-phase strategy through GMP manufacturing across viral vectors, autologous/allogeneic cell therapies, and RNA technologies.